Attached files

file filename
EX-99.1 - Travere Therapeutics, Inc.e611323_ex99-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported)  September 18, 2013
 
 
RETROPHIN, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
000-53293
26-2383102
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
777 Third Avenue, 22nd Floor, New York, NY
10017
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code    (646) 837-5863
 
 
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨ 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
 
 
 

 
 
Item 8.01 Other Events.
 
On September 18, 2013 Retrophin, Inc. (the “Company”) issued a press release announcing its proposal to acquire Transcept Pharmaceuticals, Inc. (“Transcept”).  The press release announcing the proposal, including the full text of the proposal letter delivered to Transcept’s Board of Directors, is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
 
Item 9.01  Financial Statements and Exhibits.   
 
(d) Exhibits
 
99.1 Press Release, dated September 18, 2013
 
 
 

 
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
RETROPHIN, INC.
 
       
Date:  September 18, 2013
By:
 /s/ Marc Panoff  
   
Name: Marc Panoff
 
   
Title:   Chief Financial Officer